CN112868929A - Pig additive containing saccharicterpenin and preparation method and application thereof - Google Patents
Pig additive containing saccharicterpenin and preparation method and application thereof Download PDFInfo
- Publication number
- CN112868929A CN112868929A CN202110208980.4A CN202110208980A CN112868929A CN 112868929 A CN112868929 A CN 112868929A CN 202110208980 A CN202110208980 A CN 202110208980A CN 112868929 A CN112868929 A CN 112868929A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- additive
- extract
- saccharicterpenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000654 additive Substances 0.000 title claims abstract description 59
- 230000000996 additive effect Effects 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 62
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 41
- 108091093037 Peptide nucleic acid Proteins 0.000 claims abstract description 22
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 230000003612 virological effect Effects 0.000 claims abstract description 10
- 241000282887 Suidae Species 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 36
- 239000009636 Huang Qi Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 229920002261 Corn starch Polymers 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910021485 fumed silica Inorganic materials 0.000 claims description 7
- 238000004898 kneading Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 6
- 238000010894 electron beam technology Methods 0.000 claims description 5
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 33
- 239000002994 raw material Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 10
- 241000209094 Oryza Species 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 7
- 241000628997 Flos Species 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 230000001678 irradiating effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000009305 pseudorabies Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a saccharicterpenin-containing additive for pigs, a preparation method and application thereof, and belongs to the field of additives. The additive comprises 20-30 parts by weight of saccharicterpenin, 5-15 parts by weight of peptide nucleic acid, 10-20 parts by weight of honeysuckle extract, 5-15 parts by weight of astragalus extract, 2-10 parts by weight of alpha-monolaurin and 10-58 parts by weight of carrier. The additive can effectively improve the resistance of piglets and reduce the morbidity and mortality of viral diseases. The invention also provides a preparation method of the additive, which can ensure that all components are uniformly mixed, and the prepared additive is granular, has better moisture resistance and water solubility, and can be mixed with materials or be dissolved in water.
Description
Technical Field
The invention belongs to the field of additives, and particularly relates to a saccharicterpenin-containing additive for pigs as well as a preparation method and application thereof.
Background
Enveloped viruses are viruses in which the virion is surrounded by an outer membrane formed of glycoproteins and fats. Common enveloped viruses among porcine viruses are African swine fever, porcine reproductive and respiratory syndrome, pseudorabies, influenza, and epidemic diarrhea viruses. Among them, for piglets, the incidence of pseudorabies, influenza and epidemic diarrhea virus is high, the infectivity is extremely strong, and the influence on the growth and development of piglets is large.
The method mainly adopts strict control of virus sources and strict disinfection to isolate viruses and perform vaccination on pigs and adopts antiviral drugs and antibiotics to prevent and treat the enveloped viruses aiming at the enveloped virus diseases of the piglets, wherein the virus isolation mode is adopted to prevent and treat the enveloped virus infection, the effect of some vaccines is slow, the protection rate is low, injection stress is easy to generate, the antiviral drugs and the antibiotics can not be used as preventive drugs for a long time, the outbreak of the viral diseases is strong, the temporary treatment and remediation of a pig farm such as sheep death and reinforcement are realized, and the virus infection of piglets outbreak in the breeding farm caused by breeders is often applied in an unthinkable way.
Saccharicterpenin is a natural bioactive substance consisting of saccharides (more than or equal to 30 percent), glycoside (more than or equal to 30 percent) and organic acid, is a novel approved additive component for animals, and can effectively inhibit the replication and the transmission of viruses, stimulate the organism to generate interferon and interleukin-2, block the virus infection, reduce the incidence rate of viral diseases and reduce secondary infection. Compared with antiviral drugs and antibiotics in the prior art, the saccharicterpenin has mild property, good taste, no bitter taste of common drugs, very safe use and long-term use as a preventive additive, and therefore, the development of a novel additive containing the saccharicterpenin for pigs is very important.
Disclosure of Invention
The invention aims to provide a pig additive containing saccharicterpenin, which can effectively improve the resistance of piglets and reduce the morbidity and mortality of viral diseases.
The second purpose of the invention is to provide a preparation method of the additive, which can ensure that all components are uniformly mixed, and the prepared additive is granular, has better moisture resistance and water solubility, and can be mixed and dissolved in water.
The third purpose of the invention is to provide the application of the additive in preventing the porcine envelope viral diseases, and the additive can obviously reduce the incidence and mortality of the porcine envelope viral infectious diseases when being applied to piglet breeding.
The technical problem to be solved by the invention is realized by adopting the following technical scheme:
the invention provides a saccharicterpenin-containing additive for pigs, which comprises 20-30 parts by weight of saccharicterpenin, 5-15 parts by weight of peptide nucleic acid, 10-20 parts by weight of honeysuckle extract, 5-15 parts by weight of astragalus extract, 2-10 parts by weight of alpha-monolauric acid glyceride and 10-58 parts by weight of carrier.
The invention also provides a preparation method of the additive, which comprises the following steps:
1) mixing the saccharicterpenin, the peptide nucleic acid and the alpha-monolaurin, adding the honeysuckle extract and the astragalus extract, and continuously mixing to obtain a primary mixture;
2) micronizing the primary mixture to obtain superfine powder;
3) adding a carrier into the superfine powder, continuously mixing, adding water, carrying out extrusion granulation, and drying to obtain additive granules;
4) the obtained particles are subjected to quantitative irradiation through an electron beam generated by an electron accelerator, and the irradiation dose is 10-12 kGy.
The invention also provides application of the additive in preventing piglet cyst membrane viral diseases.
The additive for pigs containing saccharicterpenin provided by the preferred embodiment of the invention has the beneficial effects that: the raw materials in the embodiment of the invention can mutually generate a synergistic effect, wherein saccharicterpenin, peptide nucleic acid and alpha-monolaurin are mutually matched, and the virus removing capacity of the glycoferritin organism can be enhanced through the damage effect of the alpha-monolaurin on the virus capsular membrane. The honeysuckle extract and the astragalus extract are further added into the combination of the saccharicterpenin, the peptide nucleic acid and the alpha-monolaurin, and the honeysuckle extract has antiviral and antibacterial effects, so that on one hand, the resistance of the body to viruses is enhanced, and on the other hand, the honeysuckle extract can play a role in inhibiting subsequent bacterial infection of the body caused by the infection of the enveloped viruses. Experiments prove that the astragalus extract can be matched with the saccharicterpenin to enhance the immunity of organisms, and the 5 substances are added into the daily ration of sows or piglets, so that the astragalus extract can play a good role in preventing and treating the infection of the swine influenza virus, the pseudorabies virus and the porcine epidemic diarrhea virus of the piglets, and the morbidity and the mortality of the infection of the 3 viruses are obviously reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The following is a detailed description of the additives, methods of preparation and uses of the embodiments of the invention.
The additive provided by the embodiment of the invention can be dissolved in water and can also be used by mixing with feed, preferably, the additive can be added into the daily ration of a sow according to the weight percentage of 0.1 percent, and the effective components are transferred to piglets through milk; or added into the piglet diet according to the weight percentage of 0.02 percent. The additive can reduce pig cystic membrane viral diseases, and can balance the cost and effect of piglet feed.
The additive provided by the embodiment of the invention is prepared by mixing raw materials and a carrier. Wherein, the raw materials comprise 20 to 30 weight portions of saccharicterpenin, 5 to 15 weight portions of peptide nucleic acid, 10 to 20 weight portions of honeysuckle extract, 5 to 15 weight portions of astragalus extract and 2 to 10 weight portions of alpha-monolaurin, and the carrier can be selected from 10 to 58 weight portions for better matching with the raw materials.
Preferably, the additive may include saccharicterpenin 22-28 parts by weight, peptide nucleic acid 8-12 parts by weight, honeysuckle extract 12-18 parts by weight, astragalus extract 8-12 parts by weight, alpha-monolaurin 5-8 parts by weight, and a carrier 22-45 parts by weight. Optimally, the additive in this embodiment may include, for example, 25 parts by weight of saccharicterpenin, 10 parts by weight of peptide nucleic acid, 15 parts by weight of honeysuckle extract, 10 parts by weight of astragalus extract, 7 parts by weight of α -monolaurin, and 33 parts by weight of carrier. Under the optimal proportion, the comprehensive effect of the raw materials and the carrier is optimal after the raw materials and the carrier are matched.
Wherein the saccharicterpenin is a natural bioactive substance composed of saccharide (more than or equal to 30%), glycoside (more than or equal to 30%) and organic acid, is a mixture of triterpenoid saponins extracted from cake of Camellia plant seed and saccharide, and is a brown yellow, ashless and fine crystal. It can effectively inhibit the replication and spread of virus, stimulate the organism to produce interferon and interleukin-2, block virus infection, improve the conversion rate of T lymphocytes, enhance the phagocytosis rate of neutrophils and alveolar macrophages, improve the content of immunoglobulin, improve the level of antibody, reduce the morbidity and mortality of enveloped virus diseases, and stabilize the production performance of pig farms.
Peptide nucleic acid is a novel DNA analogue, and the molecule is characterized in that a pentose phosphodiester bond skeleton in DNA is replaced by a neutral peptide chain amide 2-aminoethylglycine bond, and the rest is the same as the DNA. The synthetic peptide nucleic acid PNA is complementarily hybridized with virus DNA or RNA to form a stable complementary structure, selectively interferes or blocks the expression of virus conserved genes, and blocks the normal replication of virus genes.
The emulsifying property of alpha-glycerol monolaurate can emulsify esters in the viral envelope, thereby destroying the structural integrity of the envelope, and the envelope is a special structure for the virus to enter host cells, thereby leading the enveloped virus to lose the infection capacity on the host cells. Once the virus cannot enter the host cell, the virus cannot survive, so that the glycerol monolaurate can play a role in purifying the enveloped virus, namely, the non-pestilence and blue ear virus.
The honeysuckle extract is rich in chlorogenic acid, polysaccharide, luteolin and brass components, has strong bacteriostatic power on streptococcus, staphylococcus, typhoid bacillus, dysentery bacillus, large intestine, pseudomonas aeruginosa, pneumococcus, pertussis bacillus, meningococcus and the like, and has certain curative effect on influenza and inflammation. Specifically, the honeysuckle extract in the embodiment can be obtained by extracting the following steps: honeysuckle is used as a raw material, 30-50% ethanol water solution is used as an extraction solvent, ultrasonic countercurrent extraction is carried out to prepare an extracting solution, the extracting solution is filtered and concentrated by adopting a ceramic membrane until the solid content is 30% -40%, and a concentrated extract is obtained, namely the honeysuckle extract (the weight parts of honeysuckle in the additive are calculated according to the mass of dry substances in the extract). Wherein the extraction solvent is 40% ethanol water solution, the usage amount of the extraction solvent can be 2.5 times of the mass of flos Lonicerae, the temperature of ultrasonic countercurrent extraction is 55 deg.C, the ultrasonic frequency is set to 60KHz, the relative movement speed between the extraction solvent and raw materials is 0.5m/h, and the extraction time is set to 50 min.
The radix astragali extract is rich in radix astragali polysaccharide, can be used as immunostimulant or regulator, and has antiviral, antitumor, antiaging, radioprotective, anti-stress, and antioxidant effects. Specifically, the astragalus extract in this embodiment can be obtained by extracting with the following method: taking radix astragali as raw material, decocting with 2-6 times of water at 85 deg.C, repeatedly decocting the residue for 2-3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract.
The raw materials in the embodiment of the invention can mutually generate a synergistic effect, wherein saccharicterpenin, peptide nucleic acid and alpha-monolaurin are mutually matched, and the virus removing capacity of the glycoferritin organism can be enhanced through the damage effect of the alpha-monolaurin on the virus capsular membrane. The honeysuckle extract and the astragalus extract are further added into the combination of the saccharicterpenin, the peptide nucleic acid and the alpha-monolaurin, and the honeysuckle extract has antiviral and antibacterial effects, so that on one hand, the resistance of the body to viruses is enhanced, and on the other hand, the honeysuckle extract can play a role in inhibiting subsequent bacterial infection of the body caused by the infection of the enveloped viruses. Experiments prove that the astragalus extract can be matched with the saccharicterpenin to enhance the immunity of organisms, and the 5 substances are added into the daily ration of sows or piglets, so that the astragalus extract can play a good role in preventing and treating the infection of the swine influenza virus, the pseudorabies virus and the porcine epidemic diarrhea virus of the piglets, and the morbidity and the mortality of the infection of the 3 viruses are obviously reduced.
In the preparation process, the following steps can be adopted for mixing preparation: 1) mixing saccharicterpenin, peptide nucleic acid and alpha-monolaurin, adding radix astragali extract, and mixing to obtain primary mixture; 2) pulverizing the primary mixture to 60-80 mesh to obtain fine powder; 3) adding a carrier into the fine powder, continuously mixing, adding a honeysuckle extract, kneading, extruding, granulating and drying; 4) the obtained particles are subjected to quantitative irradiation through an electron beam generated by an electron accelerator, and the irradiation dose is 10-12 kGy.
Wherein, the carrier can be pulverized into 60-80 meshes according to the same method before use in actual conditions; the extrusion granulation can be carried out by putting the kneaded raw materials into a granulator, extruding through a 24-mesh sieve plate, and drying the obtained granules at 55 deg.C under reduced pressure and vacuum to water content below 3.5%; the energy of the electron beam in the irradiation treatment was 5 MeV.
It is noted that the present inventors found that, in the process of mixing the above five raw materials, by using a common carrier such as defatted rice bran, the raw materials obtained by mixing are poor in mixing performance, must be mixed again between each use, and are liable to absorb moisture during storage, resulting in a severe caking phenomenon. The inventor improves the formula and the preparation method of the auxiliary materials through a plurality of tests, and the concrete improvement lies in that: 1) adopting a mixture of 35 parts by weight of corn starch, 60 parts by weight of defatted rice bran and 5 parts by weight of fumed silica as a carrier; 2) a granulating mode is adopted to replace the traditional mixing mode; 3) and (3) irradiating the dried particles by using electron beams with specific energy. Through the improvement of the preparation method and the carrier, the problems of easy moisture absorption and poor mixing property of the mixture can be solved; and because a certain water content is required in the granulating process, the honeysuckle extract in the form of extract can be directly used as a raw material to be mixed without adopting a powdery raw material.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
Mixing 25 parts by weight of saccharicterpenin, 10 parts by weight of peptide nucleic acid and 7 parts by weight of alpha-monolaurin, adding 10 parts by weight of astragalus extract, and continuously mixing to obtain a primary mixture; pulverizing the primary mixture to 60 mesh to obtain fine powder; adding 33 weight parts of carrier into the fine powder, mixing, adding 15 weight parts of flos Lonicerae extract (calculated on dry matter), kneading, extruding, granulating, drying, and irradiating. Wherein, the carrier consists of 35 weight parts of corn starch, 60 weight parts of defatted rice bran and 5 weight parts of fumed silica; the honeysuckle extract is prepared by carrying out ultrasonic countercurrent extraction on honeysuckle with 40% ethanol water solution to obtain an extracting solution, and filtering and concentrating the extracting solution by adopting a ceramic membrane until the solid content is 35% to obtain a concentrated extract, namely the honeysuckle extract. The radix astragali extract is prepared by decocting radix astragali with 4 times of water at 85 deg.C, decocting the residue for 3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of the extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract. The extrusion granulation adopts a 24-mesh sieve plate, and the drying adopts vacuum drying under reduced pressure at 55 ℃.
Example 2
Mixing 28 parts by weight of saccharicterpenin, 8 parts by weight of peptide nucleic acid and 6 parts by weight of alpha-monolaurin, adding 12 parts by weight of astragalus extract, and continuously mixing to obtain a primary mixture; pulverizing the primary mixture to 60 mesh to obtain fine powder; adding 34 weight parts of carrier into the fine powder, mixing, adding 12 weight parts of flos Lonicerae extract (calculated on dry matter), kneading, extruding, granulating, drying, and irradiating. Wherein, the carrier consists of 35 weight parts of corn starch, 60 weight parts of defatted rice bran and 5 weight parts of fumed silica; the honeysuckle extract is prepared by carrying out ultrasonic countercurrent extraction on honeysuckle with 40% ethanol water solution to obtain an extracting solution, and filtering and concentrating the extracting solution by adopting a ceramic membrane until the solid content is 35% to obtain a concentrated extract, namely the honeysuckle extract. The radix astragali extract is prepared by decocting radix astragali with 4 times of water at 85 deg.C, decocting the residue for 3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of the extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract. The extrusion granulation adopts a 24-mesh sieve plate, and the drying adopts vacuum drying under reduced pressure at 55 ℃.
Example 3
Mixing 25 parts by weight of saccharicterpenin, 8 parts by weight of peptide nucleic acid and 5 parts by weight of alpha-monolaurin, adding 8 parts by weight of astragalus extract, and continuously mixing to obtain a primary mixture; pulverizing the primary mixture to 80 mesh to obtain fine powder; adding 42 weight parts of carrier into the fine powder, mixing, adding 12 weight parts of flos Lonicerae extract (calculated on dry matter), kneading, extruding, granulating, drying, and irradiating. Wherein, the carrier consists of 35 weight parts of corn starch, 60 weight parts of defatted rice bran and 5 weight parts of fumed silica; the honeysuckle extract is prepared by carrying out ultrasonic countercurrent extraction on honeysuckle with 40% ethanol water solution to obtain an extracting solution, and filtering and concentrating the extracting solution by adopting a ceramic membrane until the solid content is 35% to obtain a concentrated extract, namely the honeysuckle extract. The radix astragali extract is prepared by decocting radix astragali with 4 times of water at 85 deg.C, decocting the residue for 3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of the extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract. The extrusion granulation adopts a 24-mesh sieve plate, and the drying adopts vacuum drying under reduced pressure at 55 ℃.
Example 4
Mixing 22 parts by weight of saccharicterpenin, 10 parts by weight of peptide nucleic acid and 5 parts by weight of alpha-monolaurin, adding 12 parts by weight of astragalus extract, and continuously mixing to obtain a primary mixture; pulverizing the primary mixture to 60-80 mesh to obtain fine powder; adding 36 weight parts of carrier into the fine powder, mixing, adding 15 weight parts of flos Lonicerae extract (calculated on dry matter), kneading, extruding, granulating, drying, and irradiating. Wherein, the carrier consists of 35 weight parts of corn starch, 60 weight parts of defatted rice bran and 5 weight parts of fumed silica; the honeysuckle extract is prepared by carrying out ultrasonic countercurrent extraction on honeysuckle with 40% ethanol water solution to obtain an extracting solution, and filtering and concentrating the extracting solution by adopting a ceramic membrane until the solid content is 35% to obtain a concentrated extract, namely the honeysuckle extract. The radix astragali extract is prepared by decocting radix astragali with 4 times of water at 85 deg.C, decocting the residue for 3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of the extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract. The extrusion granulation adopts a 24-mesh sieve plate, and the drying adopts vacuum drying under reduced pressure at 55 ℃.
Example 5
Mixing 25 parts by weight of saccharicterpenin, 8 parts by weight of peptide nucleic acid and 8 parts by weight of alpha-monolaurin, adding 12 parts by weight of astragalus extract, and continuously mixing to obtain a primary mixture; pulverizing the primary mixture to 60-80 mesh to obtain fine powder; adding 35 weight parts of carrier into the fine powder, mixing, adding 12 weight parts of flos Lonicerae extract (calculated on dry matter), kneading, extruding, granulating, drying, and irradiating. Wherein, the carrier consists of 35 weight parts of corn starch, 60 weight parts of defatted rice bran and 5 weight parts of fumed silica; the honeysuckle extract is prepared by carrying out ultrasonic countercurrent extraction on honeysuckle with 40% ethanol water solution to obtain an extracting solution, and filtering and concentrating the extracting solution by adopting a ceramic membrane until the solid content is 35% to obtain a concentrated extract, namely the honeysuckle extract. The radix astragali extract is prepared by decocting radix astragali with 4 times of water at 85 deg.C, decocting the residue for 3 times, mixing extractive solutions, adding anhydrous ethanol with equal volume of the extractive solution, precipitating with ethanol, collecting ethanol extract, and drying to obtain radix astragali extract. The extrusion granulation adopts a 24-mesh sieve plate, and the drying adopts vacuum drying under reduced pressure at 55 ℃.
Test example 1
The following tests were carried out on the additives prepared in examples 1 to 5 to verify the hygroscopicity of the resulting additives;
the test is carried out by simultaneously arranging a comparative example 1 (the carrier in the example 1 is replaced by 35 parts by weight of corn starch and 65 parts by weight of defatted rice bran, and other preparation methods and formulas are the same as the example 1) and a comparative example 2 (the carrier in the example 1 is replaced by 100% defatted rice bran, honeysuckle extract in raw materials needs to be used after the extract is spray-dried, and all the raw materials in the additive are directly mixed after passing through a 60-mesh sieve without a granulation step), and the measurement results are shown in a table 1:
moisture absorption measurement: weighing 1g of prepared additive, spreading the additive in a weighing bottle, precisely weighing the original sample, placing the weighing bottle in a constant temperature and humidity box with an opening, and the conditions are as follows: the temperature is 25 ℃, the relative humidity is 65%, the sample mass is weighed at different time intervals, and the moisture absorption rate of 24 hours is calculated according to the following formula; moisture absorption rate (weight of particles after moisture absorption-weight of particles before moisture absorption)/weight of particles before moisture absorption × 100%.
And (3) testing the fluidity: taking 50g of the prepared additive, slowly adding the additive from an upper funnel, and gradually accumulating the auxiliary materials on a base plate through the buffer of the funnel to form a cone until the highest cone is obtained. The height H of the cone is measured, and the angle of repose is calculated according to the following formula: a is arctg (H/R), wherein a is an angle of repose, and R is a chassis radius.
Table 1: moisture absorption test results of the additives in the examples
| Test items | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | Comparative example 1 | Comparative example 2 |
| Moisture absorption property | 2.35％ | 2.73％ | 2.46％ | 2.55％ | 2.52％ | 13.53％ | 9.42％ |
| Angle of repose | 31.5° | 31.8° | 29.7° | 29.9° | 30.6° | 45.3° | 51.2° |
It can be seen that the additives obtained in examples 1 to 5 of the present invention have significantly lower moisture absorption rates than those of comparative examples 1 to 2, have lower moisture absorption rates, and have significantly lower angles of repose than those of comparative examples 1 to 2, and are more popular.
Test example 2
Selecting 60 sows in lactation period with close body weight and close birth period, randomly dividing the sows into 6 groups, feeding 10 sows in each group by respectively adopting the additives in the examples 1-5 according to 0.1 percent (weight) of the additives in the basal ration of the sows, adding no additive in a blank control group, wherein the test time is 15 days (feeding can be started after the sows are delivered), and counting the incidence rate of epidemic influenza of piglets in a delivery room, the incidence rate of diarrhea and the death rate of the piglets in the delivery room caused by the epidemic diarrhea virus after the test is finished, wherein the results are shown in a table 2:
table 2: incidence of influenza in piglets in delivery room, incidence of diarrhea and mortality in piglets
| Numbering | Incidence of influenza | Incidence of diarrhea | Mortality rate |
| Example 1 | 55.4％ | 75.6％ | 5.6％ |
| Example 2 | 56.8％ | 78.4％ | 5.8％ |
| Example 3 | 59.2％ | 79.3％ | 6.3％ |
| Example 4 | 57.5％ | 77.5％ | 6.1％ |
| Example 5 | 55.4％ | 76.2％ | 5.9％ |
| Blank control | 100％ | 100％ | 25.3％ |
Therefore, by adding the additive in the daily ration of the sow and transferring components through the milk of the sow, the incidence rate of piglet influenza and the diarrhea incidence and mortality caused by the epidemic diarrhea virus can be effectively reduced.
Test example 3
Carrying out 25 weaned piglets confirmed to be infected by the porcine pseudorabies virus in a farm, randomly marking the weaned piglets into 2 groups, wherein the number of the experimental groups is 13, and the number of the control groups is 12; the experimental group used the additive of the invention of example 1 (added at 0.02% on the basal diet) and the control group did not. The test time is 15 days, the death rate of the weaned piglets is counted after the test is finished, and the results are shown in a table 3:
table 3: mortality rate of pseudorabies virus infection of weaned piglets
| Numbering | Total number of heads/head | Death number/head | Mortality rate |
| Example 1 | 13 heads | 3 heads | 23.1％ |
| Blank control | 12 heads | 8 heads | 66.7％ |
Therefore, the additive can obviously reduce the death rate of pseudorabies virus infection of weaned piglets.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The additive for pigs is characterized by comprising 20-30 parts by weight of saccharicterpenin, 5-15 parts by weight of peptide nucleic acid, 10-20 parts by weight of honeysuckle extract, 5-15 parts by weight of astragalus extract, 2-10 parts by weight of alpha-monolaurin and 10-58 parts by weight of carrier.
2. The additive according to claim 1, comprising 22-28 parts by weight of saccharicterpenin, 8-12 parts by weight of peptide nucleic acid, 12-18 parts by weight of honeysuckle extract, 8-12 parts by weight of astragalus extract, 5-8 parts by weight of alpha-monolaurin and 22-45 parts by weight of carrier.
3. The additive according to claim 1, comprising 25 parts by weight of saccharicterpenin, 10 parts by weight of peptide nucleic acid, 15 parts by weight of honeysuckle extract, 10 parts by weight of astragalus extract, 7 parts by weight of α -monolaurin and 33 parts by weight of carrier.
4. The additive of claim 1, wherein the honeysuckle extract is prepared by ultrasonic countercurrent extraction and concentration of honeysuckle in 30-50% ethanol solution.
5. The additive as claimed in claim 1, wherein the radix astragali extract is prepared by decocting radix astragali with 6-8 times of water, collecting extractive solution, and precipitating with ethanol.
6. The additive of claim 1, wherein the carrier is composed of 35 parts by weight of corn starch, 60 parts by weight of defatted rice bran, and 5 parts by weight of fumed silica.
7. A method for preparing the additive of claim 1, comprising the steps of:
1) mixing saccharicterpenin, peptide nucleic acid and alpha-monolaurin, adding radix astragali extract, and mixing to obtain primary mixture;
2) pulverizing the primary mixture to 60-80 mesh to obtain fine powder;
3) adding a carrier into the fine powder, continuously mixing, adding a honeysuckle extract, kneading, carrying out extrusion granulation and drying to obtain additive granules;
4) the obtained particles are subjected to quantitative irradiation through an electron beam generated by an electron accelerator, and the irradiation dose is 10-12 kGy.
8. Use of the additive according to any one of claims 1 to 6 or the additive prepared by the process according to claim 7 for the prevention of a viral disease of the piglet membranes.
9. The use of the additive according to claim 8 for the prevention of piglet's enveloped viral diseases, characterized in that the additive can be added in the daily ration of sows in a weight percentage of 0.1%, and the effective ingredients are transferred to the piglets through the milk;
or added into the piglet diet according to the weight percentage of 0.02 percent.
10. Use of the additive according to claim 9 for the prevention of diseases of the porcine enveloped virus type, said enveloped virus being at least one of porcine influenza virus, pseudorabies virus and porcine epidemic diarrhea virus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110041558 | 2021-01-13 | ||
| CN2021100415584 | 2021-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112868929A true CN112868929A (en) | 2021-06-01 |
Family
ID=76054395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110208980.4A Pending CN112868929A (en) | 2021-01-13 | 2021-02-24 | Pig additive containing saccharicterpenin and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112868929A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103060325A (en) * | 2013-01-14 | 2013-04-24 | 韩健宝 | Antisense nucleic acid and peptide nucleic acid PNA resisting against porcine epidemic diarrhea virus PEDV |
| CN105639098A (en) * | 2015-12-22 | 2016-06-08 | 山东迅达康生物科技有限公司 | Green feed additive for livestock and preparation method thereof |
| CN105749278A (en) * | 2016-05-09 | 2016-07-13 | 无锡市动物疫病预防控制中心 | Porcine pseudorabies-preventing composition, preparation method and application |
| CN106387435A (en) * | 2016-10-20 | 2017-02-15 | 中粮饲料有限公司 | Feed additive, and application thereof, as well as feed |
| CN106901007A (en) * | 2017-01-06 | 2017-06-30 | 浙江大学 | Application of the compositions of additives in the fattening pannage for improving meat quality or growth performance is prepared |
| CN109925429A (en) * | 2019-04-16 | 2019-06-25 | 江西正邦动物保健品有限公司 | A kind of compound Chinese medicinal preparation and preparation method thereof improving sow reproductive performance |
| CN110354139A (en) * | 2019-08-15 | 2019-10-22 | 武汉轻工大学 | A kind of composition of porcine epidemic diarrhea resisting virus infection and its application |
| CN111467393A (en) * | 2020-05-26 | 2020-07-31 | 浙江中法制药有限公司 | Traditional Chinese medicine composition, pig feed additive and application of pig feed additive in preparation of control agent for porcine reproductive and respiratory syndrome or swine fever |
-
2021
- 2021-02-24 CN CN202110208980.4A patent/CN112868929A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103060325A (en) * | 2013-01-14 | 2013-04-24 | 韩健宝 | Antisense nucleic acid and peptide nucleic acid PNA resisting against porcine epidemic diarrhea virus PEDV |
| CN105639098A (en) * | 2015-12-22 | 2016-06-08 | 山东迅达康生物科技有限公司 | Green feed additive for livestock and preparation method thereof |
| CN105749278A (en) * | 2016-05-09 | 2016-07-13 | 无锡市动物疫病预防控制中心 | Porcine pseudorabies-preventing composition, preparation method and application |
| CN106387435A (en) * | 2016-10-20 | 2017-02-15 | 中粮饲料有限公司 | Feed additive, and application thereof, as well as feed |
| CN106901007A (en) * | 2017-01-06 | 2017-06-30 | 浙江大学 | Application of the compositions of additives in the fattening pannage for improving meat quality or growth performance is prepared |
| CN109925429A (en) * | 2019-04-16 | 2019-06-25 | 江西正邦动物保健品有限公司 | A kind of compound Chinese medicinal preparation and preparation method thereof improving sow reproductive performance |
| CN110354139A (en) * | 2019-08-15 | 2019-10-22 | 武汉轻工大学 | A kind of composition of porcine epidemic diarrhea resisting virus infection and its application |
| CN111467393A (en) * | 2020-05-26 | 2020-07-31 | 浙江中法制药有限公司 | Traditional Chinese medicine composition, pig feed additive and application of pig feed additive in preparation of control agent for porcine reproductive and respiratory syndrome or swine fever |
Non-Patent Citations (5)
| Title |
|---|
| 吴秋珏等: "糖萜素对断奶仔猪生产性能的影响", 《畜禽业》 * |
| 李官兵: "糖萜素在母猪和仔猪饲料中应用的效果观察", 《当代畜牧》 * |
| 林观谊: "某规模化猪场猪流行性腹泻的诊治和防控措施", 《福建畜牧兽医》 * |
| 王运赣等: "《微滴喷射自由成形》", 31 October 2009 * |
| 郄彦昭等: "糖萜素在养猪生产中的研究进展", 《饲料广角》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395676B (en) | A kind of compound medicament composition for treating animal mycotoxicosis | |
| CN102813064A (en) | Plant extract feed additive for piglets | |
| CN111869796B (en) | Traditional Chinese medicine additive for piglets and using method thereof | |
| CN103316206B (en) | Chinese medicine composition for improving milk yield of sow and piglet growth performance | |
| CN102973702B (en) | Piglet yellow and white scour treatment compound traditional Chinese medicine composition and preparation method thereof | |
| CN105168807B (en) | The Chinese medicine composition and preparation method thereof for treating pig blue-ear disease | |
| JP2926145B2 (en) | Anti-disease feed and feed additives for cattle and pigs | |
| CN108096443B (en) | Medicine for eliminating toxins in livestock and poultry and improving immunity of organism, preparation method and application thereof | |
| CN111972539A (en) | Additive for improving immunity of livestock and poultry organisms and preparation method thereof | |
| CN112868929A (en) | Pig additive containing saccharicterpenin and preparation method and application thereof | |
| CN105920111A (en) | Anti-diarrhea feed additive and preparation method thereof | |
| CN113730552B (en) | Composition for improving physiological functions of livestock and poultry and preparation method thereof | |
| CN102698244B (en) | Drug composition used for preventing piglets from diarrhea and promoting piglets to grow | |
| CN102379920B (en) | Veterinary antiviral and antifebrile drug composition | |
| CN102172358B (en) | Timicosin compound preparation and preparation method and use thereof | |
| CN110812389A (en) | Soluble granule for improving pig immunity and preparation method thereof | |
| CN105250727A (en) | Traditional Chinese medicine composition for prevention and treatment of livestock diarrhea and preparation method of traditional Chinese medicine composition | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN104758390A (en) | Botanical drug compound preparation for preventing and treating porcine diarrhea and preparation method thereof | |
| CN104288260B (en) | A kind of herbal medicine of effective preventing and treating porcine respiratory disease | |
| KR20190082581A (en) | Composition for preventing or treating infectious disease containing extract of Celastrus orbiculatus Thunb | |
| CN111544570B (en) | Antiviral preparation added with antibacterial peptide and preparation method thereof | |
| CN108653498B (en) | Spleen-tonifying and growth-promoting pharmaceutical composition and application thereof | |
| WO2006013000A1 (en) | The use of medicinal plants and extracts thereof with growth promoting activity in veterinary medicine and zootechnics | |
| CN118045047A (en) | Bufonis venenum granule prepared by superfine pulverizing technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210601 |